

Supplementary Material 1 PRISMA NMA Checklist of Items to Include When Reporting A Systematic Review Involving a Network Meta-analysis

Section/Topic	Item #	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review <i>incorporating a network meta-analysis (or related form of meta-analysis)</i> .	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: Background: main objectives Methods: data sources; study eligibility criteria, participants, and interventions; study appraisal; and <i>synthesis methods, such as network meta-analysis</i> . Results: number of studies and participants identified; summary estimates with corresponding confidence/credible intervals; <i>treatment rankings may also be discussed. Authors may choose to summarize pairwise comparisons against a chosen treatment included in their analyses for brevity.</i> Discussion/Conclusions: limitations; conclusions and implications of findings. Other: primary source of funding; systematic review registration number with registry name.	1-2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known, <i>including mention of why a network meta-analysis has been conducted</i> .	2-3
Objectives	4	Provide an explicit statement of questions being addressed, with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3-4
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists and if and where it can be accessed (e.g., Web address); and, if available, provide registration information, including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. <i>Clearly describe eligible treatments included in the treatment network, and note whether any have been clustered or merged into the same node (with justification)</i> .	4-5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4-5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5
Geometry of the network	S1	Describe methods used to explore the geometry of the treatment network under study and potential biases related to it. This should include how the evidence base has been graphically summarized for presentation, and what characteristics were compiled and used to describe the evidence base to readers.	6
Risk of bias within individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means). <i>Also describe the use of additional summary measures assessed, such as treatment rankings and surface under the cumulative ranking curve (SUCRA) values, as well as modified approaches used to present summary findings from meta-analyses.</i>	5
Planned methods of analysis	14	Describe the methods of handling data and combining results of studies for each network meta-analysis. This should include, but not be limited to: <ul style="list-style-type: none"> • <i>Handling of multi-arm trials;</i> • <i>Selection of variance structure;</i> • <i>Selection of prior distributions in Bayesian analyses; and</i> • <i>Assessment of model fit.</i> 	5-6
Assessment of Inconsistency	S2	Describe the statistical methods used to evaluate the agreement of direct and indirect evidence in the treatment network(s) studied. Describe efforts taken to address its presence when found.	6
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses if done, indicating which were pre-specified. This may include, but not be limited to, the following: <ul style="list-style-type: none"> • Sensitivity or subgroup analyses; • Meta-regression analyses; • <i>Alternative formulations of the treatment network; and</i> • <i>Use of alternative prior distributions for Bayesian analyses (if applicable).</i> 	5-6

RESULTS†			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Presentation of network structure	S3	Provide a network graph of the included studies to enable visualization of the geometry of the treatment network.	24-25
Summary of network geometry	S4	Provide a brief overview of characteristics of the treatment network. This may include commentary on the abundance of trials and randomized patients for the different interventions and pairwise comparisons in the network, gaps of evidence in the treatment network, and potential biases reflected by the network structure.	6-7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	24
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment.	24
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: 1) simple summary data for each intervention group, and 2) effect estimates and confidence intervals. <i>Modified approaches may be needed to deal with information from larger networks.</i>	7-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence/credible intervals. <i>In larger networks, authors may focus on comparisons versus a particular comparator (e.g. placebo or standard care), with full findings presented in an appendix. League tables and forest plots may be considered to summarize pairwise comparisons.</i> If additional summary measures were explored (such as treatment rankings), these should also be presented.	7-11
Exploration for inconsistency	S5	Describe results from investigations of inconsistency. This may include such information as measures of model fit to compare consistency and inconsistency models, <i>P</i> values from statistical tests, or summary of inconsistency estimates from different parts of the treatment network.	7-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies for the evidence base being studied.	25
Results of additional analyses	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression analyses, <i>alternative network geometries studied, alternative choice of prior distributions for Bayesian analyses,</i> and so forth).	25
DISCUSSION			
Summary of evidence	24	Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy-makers).	11-14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). <i>Comment on the validity of the assumptions, such as transitivity and consistency. Comment on any concerns regarding network geometry (e.g., avoidance of certain comparisons).</i>	14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14-15
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. This should also include information regarding whether funding has been received from manufacturers of treatments in the network and/or whether some of the authors are content experts with professional conflicts of interest that could affect use of treatments in the network.	15

PICOS = population, intervention, comparators, outcomes, study design.

* Text in italics indicates wording specific to reporting of network meta-analyses that has been added to guidance from the PRISMA statement.

† Authors may wish to plan for use of appendices to present all relevant information in full detail for items in this section.

Supplementary Material 2 Search strategy

Pubmed

("tuberculosis, meningeal"[MeSH Terms] OR (("Meningeal"[All Fields] OR "meninges"[MeSH Terms] OR "meninges"[All Fields] OR "meninge"[All Fields] OR "meningism"[MeSH Terms] OR "meningism"[All Fields] OR "meningisms"[All Fields] OR "Meningitis"[MeSH Terms] OR "Meningitis"[All Fields] OR "Meningitides"[All Fields]) AND "Tuberculosos"[Title/Abstract] OR "meningeal tuberculosis"[Title/Abstract] OR "tuberculosis meningeal"[Title/Abstract] OR ("tuberculosi"[All Fields] OR "Tuberculosis"[MeSH Terms] OR "Tuberculosis"[All Fields] OR "Tuberculoses"[All Fields] OR "tuberculosis s"[All Fields]) AND "Meningeal"[Title/Abstract] OR "tb meningitis"[Title/Abstract] OR "tb meningitides"[Title/Abstract] OR "tubercular meningitis"[Title/Abstract] OR ("Meningeal"[All Fields] OR "meninges"[MeSH Terms] OR "meninges"[All Fields] OR "meninge"[All Fields] OR "meningism"[MeSH Terms] OR "meningism"[All Fields] OR "meningisms"[All Fields] OR "Meningitis"[MeSH Terms] OR "Meningitis"[All Fields] OR "Meningitides"[All Fields]) AND "Tubercular"[Title/Abstract] OR "meningitis tubercular"[Title/Abstract] OR ("Tubercular"[All Fields] OR "tuberculars"[All Fields] AND "Meningitides"[Title/Abstract] OR "meningitis tuberculosus"[Title/Abstract] OR ("Meningeal"[All Fields] OR "meninges"[MeSH Terms] OR "meninges"[All Fields] OR "meninge"[All Fields] OR "meningism"[MeSH Terms] OR "meningism"[All Fields] OR "meningisms"[All Fields] OR "Meningitis"[MeSH Terms] OR "Meningitis"[All Fields] OR "Meningitides"[All Fields]) AND "Tuberculous"[Title/Abstract] OR "tuberculous meningitis"[Title/Abstract] OR "tuberculosis meningitis"[Title/Abstract] OR ("Meningeal"[All Fields] OR "meninges"[MeSH Terms] OR "meninges"[All Fields] OR "meninge"[All Fields] OR "meningism"[MeSH Terms] OR "meningism"[All Fields] OR "meningisms"[All Fields] OR "Meningitis"[MeSH Terms] OR "Meningitis"[All Fields] OR "Meningitides"[All Fields]) AND "Tuberculosus"[Title/Abstract] OR "meningitis tuberculosus"[Title/Abstract] OR ("tuberculosi"[All Fields] OR "Tuberculosis"[MeSH Terms] OR "Tuberculosis"[All Fields] OR "Tuberculoses"[All Fields] OR "tuberculosis s"[All Fields]) AND "Meningitides"[Title/Abstract] OR "tuberculous hypertrophic pachymeningitis"[Title/Abstract] OR ("hypertrophical"[All Fields] OR "hypertrophy"[MeSH Terms] OR "hypertrophy"[All Fields] OR "Hypertrophic"[All Fields] AND "Meningitis"[MeSH Terms] OR "Meningitis"[All Fields]) AND "Tuberculosus"[Title/Abstract] OR "Meningitis"[Title/Abstract] OR ("hypertrophical"[All Fields] OR "hypertrophy"[MeSH Terms] OR "hypertrophy"[All Fields] OR "Hypertrophic"[All Fields]) AND ("Meningitis"[MeSH Terms] OR "Meningitis"[All Fields] OR "Pachymeningitis"[All Fields] OR "pachymeningeal"[All Fields] OR "pachymeninges"[All Fields]) AND "Tuberculosus"[Title/Abstract] OR ("Meningitis"[MeSH Terms] OR "Meningitis"[All Fields] AND "tuberculous hypertrophic"[Title/Abstract] OR ("Meningitis"[MeSH Terms] OR "Meningitis"[All Fields] OR "Pachymeningitis"[All Fields] OR "pachymeningeal"[All Fields] OR "pachymeninges"[All Fields] AND "tuberculous hypertrophic"[Title/Abstract])) AND ("randomized controlled trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract])

Embase

No.	Query	Results
#27	#25 AND #26	126
#26	'random':ab,ti OR 'placebo':ab,ti OR 'double-blind':ab,ti	1046759
#25	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24	12360
#24	'tuberculous hypertrophic pachymeningitides':ab,ti	0
#23	'pachymeningitis, tuberculous hypertrophic':ab,ti	0
#22	'pachymeningitides, tuberculous hypertrophic':ab,ti	0
#21	'hypertrophic pachymeningitis, tuberculous':ab,ti	0
#20	'hypertrophic pachymeningitides, tuberculous':ab,ti	0
#19	'tuberculous hypertrophic pachymeningitis':ab,ti	9
#18	'tuberculosis meningitides':ab,ti	0
#17	'meningitis, tuberculosis':ab,ti	59
#16	'meningitides, tuberculosis':ab,ti	1
#15	'tuberculosis meningitis':ab,ti	473
#14	'tuberculous meningitis':ab,ti	6805
#13	'tuberculous meningitides':ab,ti	3
#12	'meningitides, tuberculous':ab,ti	0
#11	'meningitis, tuberculous':ab,ti	56
#10	'tubercular meningitides':ab,ti	1
#9	'meningitis, tubercular':ab,ti	7
#8	'meningitides, tubercular':ab,ti	0
#7	'tubercular meningitis':ab,ti	572
#6	'tb meningitides':ab,ti	1
#5	'tb meningitis':ab,ti	660
#4	'tuberculoses, meningeal':ab,ti	0
#3	'meningeal tuberculosis':ab,ti	485
#2	'meningeal tuberculoses':ab,ti	0
#1	'tuberculous meningitis'/exp	10812

Web of Science

#	Search Query	Database	Results
1	TS=(Tuberculosis, Meningeal) OR TS=(Meningeal Tuberculoses) OR TS=(Meningeal Tuberculosis) OR TS=(Tuberculoses, Meningeal) OR TS=(TB Meningitis) OR TS=(TB Meningitides) OR TS=(Tubercular Meningitis) OR TS=(Meningitides, Tubercular) OR TS=(Meningitis, Tubercular) OR TS=(Tubercular Meningitides) OR TS=(Meningitis, Tuberculosus) OR TS=(Meningitides, Tuberculosus) OR TS=(Tuberculosus Meningitis) OR TS=(Meningitis, Tuberculosis) OR TS=(Meningitides, Tuberculosis) OR TS=(Tuberculosis Meningitis) OR TS=(Tuberculosis Hypertrophic Pachymeningitis) OR TS=(Hypertrophic Pachymeningitides, Tuberculosus) OR TS=(Hypertrophic Pachymeningitis, Tuberculosus) OR TS=(Pachymeningitides, Tuberculous Hypertrophic) OR TS=(Pachymeningitis, Tuberculous Hypertrophic) OR TS=(Tuberculous Hypertrophic Pachymeningitides)	Web of Science Core Collection	4918
2	TS=(random) OR TS=(placebo) OR TS=(double-blind) OR TS=(randomized controlled trial) OR TS=(randomized)	Web of Science Core Collection	2249262
3	#2 AND #1	Web of Science Core Collection	248

Cochrane library

ID	Search Hits
#1	MeSH descriptor: [Tuberculosis, Meningeal] explode all trees 116
#2	(Meningeal Tuberculoses):ti,ab,kw OR (Meningeal Tuberculosis):ti,ab,kw OR (Tuberculoses, Meningeal):ti,ab,kw OR (TB Meningitis):ti,ab,kw OR (TB Meningitides):ti,ab,kw 187
#3	(Tubercular Meningitis):ti,ab,kw OR (Meningitides, Tubercular):ti,ab,kw OR (Meningitis, Tubercular):ti,ab,kw OR (Tubercular Meningitides):ti,ab,kw OR (Meningitis, Tuberculosis):ti,ab,kw 236
#4	(Meningitides, Tuberculosis):ti,ab,kw OR (Tuberculous Meningitides):ti,ab,kw OR (Tuberculous Meningitis):ti,ab,kw OR (Tuberculosis Meningitis):ti,ab,kw OR (Meningitides, Tuberculosis):ti,ab,kw303
#5	(Meningitis, Tuberculosis):ti,ab,kw OR (Tuberculosis Meningitides):ti,ab,kw OR (Tuberculous Hypertrophic Pachymeningitis):ti,ab,kw OR (Hypertrophic Pachymeningitides, Tuberculosis):ti,ab,kw OR (Hypertrophic Pachymeningitis, Tuberculosis):ti,ab,kw 232
#6	(Pachymeningitides, Tuberculous Hypertrophic):ti,ab,kw OR (Pachymeningitis, Tuberculous Hypertrophic):ti,ab,kw OR (Tuberculous Hypertrophic Pachymeningitides):ti,ab,kw 0
#7	#1 or #2 or #3 or #4 or #5 or #6 331

Supplementary Material 3 Statistical analysis of relevant indicators and heterogeneity test

PART I MCMC parameters

Number of chains=4






Total iterations per chain=80000(mortality,gastrointestinal)/50000(other outcome)

Burn-in period=20000



PART II Bayesian model reporting

Outcome	Model	$J^2(\%)$	DIC	PSRF(multivariate)
Mortality	Fixed effect	8	119.02644	1
	Random effect	5	120.17390	1.01
Gastrointestinal events	Fixed effect	3	47.60776	1
	Random effect	0.6	48.92341	1
Neurological events	Fixed effect	4	74.04	1
	Random effect	0	74.56	1.01
Hepatic events	Fixed effect	9	35.00	1
	Random effect	5	35.73	1
tuberculoma and other extra-cerebr	Fixed effect	6	31.42	1
	Random effect	3	32.83	1.01


PART III Network inconsistency and heterogeneity assessment




graph a heterogeneity assessment of mortality




graph b heterogeneity assessment of gastrointestinal events



graph c heterogeneity assessment of neurological events



graph d heterogeneity assessment of hepatic events



graph e heterogeneity assessment of tuberculoma and other extra-cerebrospinal tuberculosis

PART III Classification of outcomes

1. ****Death****
2. ****Gastrointestinal events****
 - Gastrointestinal blood loss
 - Gastritis
 - Gastrointestinal bleeding
 - Gastrointestinal events
 - Melena
 - Vomiting
 - Vomiting blood
 - Nausea
 - Diarrhea
 - Severe abdominal pain
 - Abdominal pain
 - Abdominal discomfort
 - Gastrointestinal disorders
 - Bleeding
 - Severe vomiting or diarrhoea
3. ****Neurological events****
 - Hemiparesis
 - Multiple palsies
 - Hemiplegia
 - Limbs paralysis
 - Paraplegia
 - Quadriplegia
 - Spastic tetraparesis
 - Paraparesis
 - New-onset lower limb weakness
 - Weakened muscle strength

- Optic atrophy
- Optic neuropathy
- Blurring of vision, loss of visual field, or blindness
- Eye disorders
- Visual acuity
- Papilloedema
- Temporal palor of optic discs
- Deafness
- Impairment of hearing
- Hearing decreased
- Ear and labyrinth disorders
- Encephalopathy
- Deterioration of consciousness
- Altered sensorium
- Fall in GCS 2 points for 2 days
- Sensory loss with level
- Patchy sensory loss
- Sensory loss in root distribution
- Seizures
- Cerebrovascular events
- Mental retardation
- Ptosis
- Meningeal signs
- Spinal arachnoiditis
- Paralysis of bladder
- Neurology deterioration
- Neurological events
- Altered mental status
- Peripheral neuropathy
- Neurological Sequelae (Included Inflammatory myelopathy, Anterior cord ischemia, Radiculopathy or arachnoiditis, Clinical presentation of stroke)
- New isolated cranial nerve palsy
- Neurological IRIS
- Nervous system disorders
- Psychiatric disorders

4. **Hepatic events**

- Jaundice
- Hepatosplenomegaly
- Hepatitis
- Hepatotoxicity
- Liver function disturbance
- Hepatic events
- Liver function damage
- Elevated bilirubin
- Elevated alanine transaminase
- Hepatobiliary disorders
- Liver dysfunction

5. **Tuberculoma and other extra-cerebrospinal tuberculosis**

- Tuberculoma
- Tuberculous hip
- Extra meningeal tuberculosis
- Miliary TB

Supplementary Material 4 Code for analysis

```
outcomedata <- read.csv("outcome.csv")#导入数据
outcomenw <- mtc.network(data = outcomedata, description = "outcome network")
dev.new()
pdf(onefile = FALSE, "outcome_network.pdf")
plot(outcomenw, use.description = TRUE)
dev.off()
outcomemdl <- mtc.model(outcomenw, type = "consistency", factor = 2.5, n.chain = 4,
  likelihood="binom", link="logit", linearModel="fixed")
outcomerslt <- mtc.run(outcomemdl, n.adapt = 20000, n.iter = 50000, thin = 1)
summary(outcomerslt)
gelman.diag(outcomerslt)
dev.new()
pdf(onefile = FALSE, "outcome_forest.pdf")
forest(relative.effect(outcomerslt, t1 = "standard"), use.description = TRUE)
dev.off()
dev.new()
outcomerk <- rank.probability(outcomerslt, preferredDirection = -1)
pdf(onefile = FALSE, "outcome_rank.pdf")
plot(outcomerk, beside = TRUE)
dev.off()
outcomescrk <- sucra(outcomerk)
print(outcomescrk)
write.csv(outcomescrk, "outcomescrk.csv")
outcomerk_new <- convert_matrix_to_df(outcomerk)
P<-ggplot(outcomerk_new,aes(x=rank,y=prob, colour=treatment)) +
  geom_line(size=2,lty="solid")
p1<-P+geom_point(size=2)+
  labs(x="rank", y="Cumulative probability")+
  theme(axis.text = element_text(size=12),
    axis.title=element_text(size=15),
    panel.background=element_blank(),
    axis.line = element_line(color="black"),
    legend.title=element_text(size=15,color="black"),
    legend.position="bottom")
p1
ggsave("outcome_sucra.pdf", plot = p1, width = 9, height = 6, units = "in")
outcometb <-relative.effect.table(outcomerslt)
outcomeltb <-round(exp(outcometb), 2)
write.csv(outcomeltb, "outcomeltb.csv")
outcomens <- mtc.nodesplit(outcomenw, comparisons = mtc.nodesplit.comparisons(outcomenw),
  likelihood="binom", link="log", linearModel="fixed")
dev.new()
pdf(onefile = TRUE, "outcome_ns.pdf", width = 10)
plot(summary(outcomens))
dev.off()
outcomeht <- mtc.anohe(outcomenw, likelihood="binom", link="log", linearModel="fixed")
dev.new()
pdf(onefile = TRUE, "outcome_anohe.pdf", width = 10)
plot(summary(outcomeht))
dev.off()
```

Supplementary Material 5 Detailed treatment regimens

Study	Intervention of interest	standard treatment
LORBER 1954	standard treatment isoniazid : 5-20mg/kg PO/QD+standard treatment	Streptomycin: IT PAS: PO/QD no definite dosage
Aderson 1957	standard treatment isoniazid:10mg/ kg QD +standard treatment	streptomycin 1g IV/IM QD;6 month (addition medicine time for compromise group) PAS maximum 15g QD
OToole 1969	standard treatment dexamethasone: 2.25mg Q6h reduce gradually+standard treatment	isoniazid 10mg/kg IM/QD streptomycin 20mg/kg QD
Ghosh 1971	standard treatment prednisolone: 2mg/kg PO/QD+standard treatment hydrocortisone: 25mg/kg IT/QD+standard treatment	streptomycin 40mg/kg IM/QD isonicotinic acid hydrazide 20mg/kg PO/QD thiacetazone 3.5mg/kg PO/QD (after streptomycin)
Rahjoc 1980	Rifampicin:10-15 mg/kg PO/QD+standard treatment PAS: 200-300 mg/kg PO/QD+standard treatment	Isoniazid: 20 mg/kg PO/QD Streptomycin: 30-50 mg/kg IM/QD Corticosteroid: IM for 3 days (no specific drug) , Prednisone 1-3 mg/kg/day PO
Girgis 1991	standard treatment dexamethasone : adults:12mg IM/QD; children (<25kg) 8mg IM/QD+standard treatment	Ethambutol: 25 mg/kg PO/QD ×6 week → 15 mg/kg PO/QD (maximum 1200mg) Isoniazid: 10 mg/kg IM/QD ×3 week → 10 mg/kg PO/QD (maximum 600mg) Streptomycin: 25 mg/kg IM/QD (maximum 1000mg)
Kumarvelu 1994	standard treatment dexamethasone:adults: 16mg IV in 4 divided doses daily ×7days → 8mg PO/QD ×21days; children: 0.6mg/kg/day IV in 4 divided doses ×7days → 0.3mg/kg/day PO/QD ×21days+standard treatment	Rifampicin: 450mg PO/QD (adults); 15mg/kg PO/QD (children) Isoniazid: 300mg PO/QD (adults); 10mg/kg PO/QD (children) Pyrazinamide: 1500mg PO/QD (adults); 30mg/kg PO/QD (children)
Schoeman 1997	standard treatment prednisone: 2 mg/kg PO/QD (initial 16 patients) → 4 mg/kg PO/QD (subsequent 54 patients)+standard treatment	Isoniazid: 20 mg/kg PO/QD Rifampicin: 20 mg/kg PO/QD Ethionamide: 20 mg/kg PO/QD Pyrazinamide: 40 mg/kg PO/QD
Thwaites 2004	standard treatment dexamethasone:Grade II/III: Dexamethasone sodium phosphate: IV/QD 0.4 → 0.3 → 0.2 → 0.1 mg/kg/day (weekly reduction) Dexamethasone: PO/QD Start 4 mg/day → ↓ 1 mg/week+standard treatment Grade I: Dexamethasone sodium phosphate: IV/QD 0.3 → 0.2 mg/kg/day (weekly reduction) Dexamethasone: PO/QD 0.1 mg/kg/day → ↓ 1 mg/week+standard treatment	Isoniazid: 5 mg/kg PO/QD Rifampin: 10 mg/kg PO/QD Pyrazinamide: 25 mg/kg PO/QD (max 2 g/day) Plus: - Non-HIV: Streptomycin: 20 mg/kg IM/QD (max 1 g/day) - HIV/Previously treated: Ethambutol: 20 mg/kg PO/QD (max 1.2 g/day)
Malhotra 2009	standard treatment dexamethasone: Weeks 1-4: IV/QD - Week 1: 0.4 mg/kg/day - Week 2: 0.3 mg/kg/day - Week 3: 0.2 mg/kg/day - Week 4: 0.1 mg/kg/day - Weeks 5-8: PO/QD - Week 5: 4 mg/day - Week 6: 3 mg/day - Week 7: 2 mg/day - Week 8: 1 mg/day+standard treatment methylprednisolone: Days 1-5: IV/QD 1 g/day (if >50 kg) or 20 mg/kg/day (if ≤50 kg)+standard treatment	Rifampicin: 15 mg/kg PO/QD Isoniazid: 10 mg/kg PO/QD Pyrazinamide: 30 mg/kg PO/QD Ethambutol: 20 mg/kg PO/QD or Streptomycin: 15 mg/kg IM/QD (for first 2 months) → Then Rifampicin + Isoniazid only (≥7 months)
Misra 2010	standard treatment aspirin:150 mg PO/QD (fixed dose)+standard treatment	Rifampicin: 10 mg/kg PO/QD Isoniazid: 5 mg/kg PO/QD Pyrazinamide: 25 mg/kg PO/QD Ethambutol: 15 mg/kg PO/QD Plus (if indicated): - Prednisolone: 0.5-1.0 mg/kg PO/QD - OR Dexamethasone: 0.4 mg/kg PO/QD
Schoeman 2011	standard treatment low-dose aspirin: 75 mg PO/QD (fixed dose)+standard treatment high-dose aspirin: 100 mg/kg PO/TID (divided into 3 doses)+standard treatment pretreated aspirin: 75 mg PO/QD (fixed dose)+standard treatment	Isoniazid: 20 mg/kg PO/QD Rifampicin: 20 mg/kg PO/QD Ethionamide: 20 mg/kg PO/QD Pyrazinamide: 40 mg/kg PO/QD (max 1200 mg/day) Prednisone: 2 mg/kg PO/QD (max 60 mg/day)
Thwaites 2011	standard treatment Ciprofloxacin: 750mg PO/Q12H+standard treatment Gatifloxacin: 500mg PO/Q12H+standard treatment Levofloxacin: 400mg PO/QD+standard treatment	Isoniazid PO/QD (5 mg/kg, max 300 mg); Rifampin PO/QD (10 mg/kg, max 600 mg); Pyrazinamide PO/QD (30 mg/kg, max 2 g/day); Streptomycin IM/QD (20 mg/kg, max 1 g/day); Dexamethasone (per protocol)
Torok 2011	standard treatment dexamethasone: 0.3-0.4 mg/kg IV QD+standard treatment	Initial Phase (3 months): Isoniazid 5 mg/kg PO QD max 300 mg Rifampin 10 mg/kg PO QD max 600 mg Pyrazinamide 25 mg/kg PO QD max 2 g/day Streptomycin 20 mg/kg IM QD max 1 g/day Continuation Phase (6 months): Isoniazid 5 mg/kg PO QD max 300 mg Rifampin 10 mg/kg PO QD max 600 mg
Kalita 2014	levofloxacin: 10 mg/kg PO QD max 500 mg +standard treatment standard treatment dose rifampicin:10 mg/kg PO QD max 450 mg +standard treatment	Isoniazid 5 mg/kg PO QD max 300 mg; Pyrazinamide 25 mg/kg PO QD max 1500 mg; Ethambutol 15 mg/kg PO QD max 800 mg; Prednisolone 0.5 mg/kg PO QD max 40 mg; Aspirin 150 mg PO QD
Heemskerk 2016	standard treatment levofloxacin:20 mg/kg PO/QD for first 8 weeks+standard treatment	Isoniazid: 5 mg/kg PO/QD max 300 mg/day Rifampin: 10 mg/kg PO/QD Pyrazinamide: 25 mg/kg PO/QD max 2 g/day for first 3 months Ethambutol: 20 mg/kg PO/QD max 1.2 g/day for first 3 months Streptomycin: 20 mg/kg IM/QD max 1 g/day for first 3 months (if previously treated)
Kalita 2016	standard treatment levofloxacin:10 mg/kg PO/QD+standard treatment	Rifampicin: 10 mg/kg PO/QD Isoniazid: 5 mg/kg PO/QD Pyrazinamide: 25 mg/kg PO/QD Ethambutol: 15 mg/kg PO/QD Prednisolone: 0.5 mg/kg PO/QD for 1 month then taper over next 1 month Aspirin: 150 mg PO/QD

Amin 2017	standard treatment	Rifampicin: 15 mg/kg PO/QD Isoniazid: 10 mg/kg PO/QD Pyrazinamide: 25 mg/kg PO/QD Ethambutol: 15 mg/kg PO/QD Prednisolone: 1-2 mg/kg PO/QD for 4 weeks then taper over next 4 weeks
	aspirin:60 mg/kg PO/BID+standard treatment	
Dian 2018	standard treatment	Rifampicin: 10 mg/kg PO/QD Isoniazid + Pyrazinamide + Ethambutol (doses per Indonesian national guidelines) Dexamethasone: IV during hospitalization → PO after discharge (dosing/tapering per Vietnamese study)
	high dose rifampicin:30 mg/kg QD+standard treatment	
Mai 2018	standard treatment	Isoniazid 5 mg/kg PO/QD max 300 mg Rifampicin 10 mg/kg PO/QD Pyrazinamide 25 mg/kg PO/QD max 2 g Ethambutol 20 mg/kg PO/QD max 1.2 g Streptomycin 20 mg/kg IM/QD max 1 g for 3 months Isoniazid 5 mg/kg PO/QD max 300 mg + Rifampicin 10 mg/kg PO/QD for 6 months Dexamethasone PO per protocol Ranitidine 300 mg PO/QD
	aspirin : Aspirin 81 mg PO/QD + Placebo 500 mg PO/BID+standard treatment OR Aspirin 81 mg PO/QD + Aspirin 500 mg PO/BID+standard treatment	
Misra 2018	standard treatment	Rifampicin 10 mg/kg PO/QD Isoniazid 5 mg/kg PO/QD Pyrazinamide 25 mg/kg PO/QD Ethambutol 15 mg/kg PO/QD Prednisolone 0.5 mg/kg PO/QD Aspirin 150 mg PO/QD
	Fludrocortisone: 0.1-0.4 mg PO/QD+standard treatment	
Diao 2020	standard treatment	Streptomycin 0.75 g IM/QD Isoniazid 0.3 g PO/QD Rifampin 0.45 g PO/QD Ethambutol 0.75 g PO/QD Pyrazinamide 1.5 g PO/QD Continuation Phase (6 months): Isoniazid 0.3 g PO/QD Rifampin 0.45 g PO/QD
	Methylprednisolone:Methylprednisolone 500 mg IV/QD ×7 days → 80 mg PO/QD → Tapered to maintenance dose PO (total 3 months)+standard treatment	
Cresswell 2021	standard treatment	Rifampicin: PO 10mg/kg/QD Isoniazid: PO 5mg/kg/QD Pyrazinamide: PO 25mg/kg/QD Ethambutol: PO 20mg/kg/QD Dexamethasone:Week 1: IV 0.4mg/kg/QD Week 2: IV 0.3mg/kg/QD Thereafter: Prednisolone PO 80mg/QD, tapered to stop over 6 weeks.
	high_dose_rifampicin:20mg/kg+standard treatment IV;35mg/kg PO+standard treatment	
Paradkar 2022	standard treatment :	Isoniazid 5 mg/kg PO/QD, Rifampicin 15 mg/kg PO/QD, Pyrazinamide 25 mg/kg PO/QD, Ethambutol 20 mg/kg PO/QD
	high_dose_Rifampicin: 30 mg/kg PO/QD+standard treatment	
	high_dose_Rifampicin_Levofloxacin:Rifampicin 30 mg/kg PO/QD; Levofloxacin 15 mg/kg PO/QD+standard treatment	
Davis 2023	standard treatment	rifampicin 10 mg/kg, isoniazid (H) 5 mg/kg, ethambutol (E) 15 mg/kg, and pyrazinamide (Z) 25 mg/kg daily for 56 days
	aspirin : aspirin (1000 mg) daily for 56 day+standard treatment	
Donovan 2023	standard treatment	Isoniazid PO/QD (dose NS), Rifampicin PO/QD (dose NS), Pyrazinamide PO/QD (dose NS), Ethambutol PO/QD (dose NS)
	dexamethasone: Grade I: IV 0.3 mg/kg/QD × week 1 → 0.2 mg/kg/QD × week 2 → 0.1 mg/kg/QD × week 3; then PO 3 mg/QD × week 4 → 2 mg/QD × week 5 → 1 mg/QD × week 6+standard treatment Grade II/III: IV 0.4 mg/kg/QD × week 1 → 0.3 mg/kg/QD × week 2 → 0.2 mg/kg/QD × week 3 → 0.1 mg/kg/QD × week 4; then PO 4 mg/QD × week 5 → 3 mg/QD × week 6 → 2 mg/QD × week 7 → 1 mg/QD × week 8+standard treatment	
Sahib 2023	standard treatment	Rifampicin: 10 mg/kg PO/QD Isoniazid: 5 mg/kg PO/QD Pyrazinamide: 15–30 mg/kg PO/QD Ethambutol: 15 mg/kg PO/QD or Streptomycin: 0.75–1 g IM/QD Dexamethasone or Prednisolone (standard treatment dosing for TBM, per clinician's judgment)
	linezolid: Linezolid: 600 mg PO/BID for 28 days+standard treatment	
Bhatia 2025	standard treatment	Rifampicin 10 mg/kg PO/QD, Isoniazid 5 mg/kg PO/QD, Pyrazinamide 15–30 mg/kg PO/QD, and Ethambutol 15 mg/kg PO/QD or Streptomycin 0.75–1 g IM/QD Dexamethasone IV/PO 0.4 mg/kg/day (min. 8 weeks)
	aspirin: 75 mg PO/QD for 90 days+standard treatment	
	clopidogrel: 75 mg PO/QD for 90 days+standard treatment	
Chow 2025	standard treatment	Rifampin: 10 mg/kg PO/QD for 4 weeks Isoniazid: Weight-based PO/QD Pyrazinamide: Weight-based PO/QD Ethambutol: Weight-based PO/QD Dexamethasone: 0.4 mg/kg IV/PO/QD (Week 1), 0.3 mg/kg IV/PO/QD (Week 2), then prednisone taper over 6 weeks Vitamin B6: 50 mg PO/QD
	linezolid:1200 mg PO/QD for 4 weeks+standard treatment	
	high dose rifampicin:35 mg/kg PO/QD for 4 weeks+standard treatment	

NS: Not specified in main text (standard treatment doses per national guidelines)

IV: Intravenous

PO: Oral

QD: Once daily

BID: Twice in a day

IM: intramuscular injection

IT: intrathecal injection


0.65 (0.41, 1.05)	0.42 (0.05, 2.23)	0.78 (0.17, 3.28)	0.83 (0.59, 1.17)	1.9 (0.41, 9.76)	0.46 (0.05, 2.44)	2.27 (0.42, 14.31)	2.05 (0.66, 6.7)	0.31 (0.01, 4.87)	levofloxa cin	1.92 (0.54, 7.05)	linezolid	0.74 (0.15, 3.56)	methypred nisolone	0.26 (0.04, 1.79)	PAS	0.8 (0.16, 3.87)	1.09 (0.28, 4.15)	4.12 (0.6, 29.04)	prednisol one	2.46 (0.55, 12.7)	predniso ne	0.62 (0.24, 1.61)	0.25 (0.07, 0.79)	standard	0.37 (0.15, 0.88)	standard _dose_rif ampicin
1.26 (0.34, 4.7)	0.8 (0.07, 6.54)	1.5 (0.22, 9.91)	1.6 (0.46, 5.75)	3.68 (0.52, 28.08)	0.86 (0.08, 7.18)	4.4 (0.54, 39.11)	3.95 (0.75, 21.91)	0.6 (0.02, 12.24)																		
0.92 (0.34, 2.63)	0.59 (0.06, 4.11)	1.11 (0.2, 6.08)	1.18 (0.47, 3.12)	2.71 (0.46, 17.32)	0.64 (0.06, 4.48)	3.23 (0.47, 24.99)	2.92 (0.69, 13.09)	0.44 (0.01, 8.03)																		
0.24 (0.04, 1.37)	0.15 (0.01, 1.67)	0.29 (0.03, 2.61)	0.31 (0.06, 1.7)	0.71 (0.07, 7.25)	0.17 (0.01, 1.82)	0.86 (0.08, 10.14)	0.77 (0.1, 5.9)	0.11 (0, 2.89)																		
1.01 (0.36, 2.84)	0.64 (0.07, 4.47)	1.2 (0.21, 6.68)	1.29 (0.48, 3.44)	2.94 (0.49, 19.37)	0.7 (0.07, 4.91)	3.52 (0.51, 27.07)	3.18 (1.05, 10.01)	0.48 (0.01, 8.78)																		
2.46 (0.75, 10.05)	1.59 (0.15, 13.34)	2.97 (0.46, 20.48)	3.13 (1, 12.28)	7.29 (1.09, 57.46)	1.72 (0.16, 14.76)	8.71 (1.12, 81.37)	7.84 (1.58, 44.54)	1.19 (0.03, 24.58)																		
0.63 (0.43, 0.91)	0.4 (0.05, 2.12)	0.75 (0.17, 3.04)	0.8 (0.67, 0.95)	1.82 (0.4, 9.09)	0.44 (0.05, 2.33)	2.17 (0.41, 13.38)	1.96 (0.65, 6.19)	0.3 (0.01, 4.61)																		
0.23 (0.09, 0.6)	0.15 (0.02, 0.96)	0.27 (0.05, 1.43)	0.29 (0.12, 0.72)	0.67 (0.12, 4.17)	0.16 (0.02, 1.05)	0.8 (0.12, 5.96)	0.72 (0.17, 3.06)	0.11 (0, 1.94)																		

Death_sscrk_sorted


X

standard_dose_rifampicin	0.111456563
PAS	0.173440938
hydrocortisone	0.195081563
high_dose_rifampicin	0.211005938
Fludrocortisone	0.246651875
standard	0.380908125
levofloxacin	0.419690313
dexamethasone	0.541425938
Clopidogrel	0.54613375
methylprednisolone	0.598108438
prednisolone	0.635600313
aspirin	0.664247188
linezolid	0.698949375
gatifloxacin	0.712467188
ciprofloxacin	0.735872813
isoniazid	0.74506125
prednisone	0.883898438




Gastrointestinal_s_anohe



Gastrointestinal_s_ns



Gastrointestinal_s_01





Gastrointestinal_sltb

OR 95% CrI						
aspirin						
0.29 (0.03, 3.05)	dexamethasone					
0.51 (0.01, 38.56)	1.72 (0.04, 73.83)	high_dose_rifampicin				
0.45 (0.04, 4.9)	1.54 (0.66, 3.59)	0.9 (0.02, 39.79)	levofloxacin			
0.24 (0, 6.95)	0.85 (0.03, 10.07)	0.46 (0, 41.6)	0.55 (0.02, 6.77)	linezolid		
0.62 (0.05, 8.37)	2.07 (0.61, 7.9)	1.23 (0.02, 61.69)	1.35 (0.35, 5.72)	2.51 (0.16, 96.14)	methylprednisolone	
0.51 (0.05, 5.01)	1.72 (1.04, 2.89)	1 (0.02, 41.76)	1.12 (0.58, 2.18)	2.01 (0.18, 65.61)	0.83 (0.23, 2.7)	standard


Gastrointestinal_sscrk sorted

	X
dexamethasone	0.226164166666667
linezolid	0.319003333333333
levofloxacin	0.489799166666667
high_dose_rifampicin	0.51898
standard	0.5776275
methylprednisolone	0.632293333333333
aspirin	0.7361325


Hepatic_s_anohe



Hepatic_s_ns



Hepatic_s_01



Hepatic_slth

OR 95% CrI


aspirin	0.49 (0.01, 17.95)	dexamethasone	0.31 (0.01, 11.4)	0.64 (0.31, 1.3)	levofloxacin	0.88 (0.02, 43.98)	1.79 (0.33, 10.31)	2.82 (0.5, 16.48)	linezolid	0.62 (0.02, 24.18)	1.27 (0.53, 3.11)	2 (0.75, 5.49)	0.71 (0.11, 4.47)	methylprednisolone	0.56 (0.02, 19.87)	1.14 (0.71, 1.83)	1.79 (1.05, 3.13)	0.64 (0.12, 3.29)	0.9 (0.39, 2.04)	standard
---------	--------------------	---------------	-------------------	------------------	--------------	--------------------	--------------------	-------------------	-----------	--------------------	-------------------	----------------	-------------------	--------------------	--------------------	-------------------	-------------------	-------------------	------------------	----------

Hepatic_sscrk sorted

X


levofloxacin	0.112411
dexamethasone	0.411174
standard	0.548007
methylprednisolone	0.592239
aspirin	0.645105
linezolid	0.691064

Neurological_s_anoh




Tuberculoma_s_forest


Compared with standard



Tuberculoma_s_01



Compared with standard



Tuberculoma_slbt


OR 95%CrI						
aspirin						
3.96 (0.67, 34.45)	dexamethasone					
1.16 (0.34, 3.98)	0.29 (0.03, 2.21)	levofloxacin				
10.26 (1.19, 311.98)	2.58 (0.19, 85.72)	9.02 (0.84, 297.53)	methylprednisolone			
7.21 (1.49, 58.58)	1.85 (0.14, 24.72)	6.31 (0.98, 60.65)	0.71 (0.02, 12.27)	prednisone		
1.27 (0.73, 2.24)	0.32 (0.04, 1.74)	1.1 (0.37, 3.32)	0.13 (0, 0.99)	0.18 (0.02, 0.77)	standard	
1.33 (0.32, 5.55)	0.33 (0.03, 2.85)	1.14 (0.55, 2.38)	0.13 (0, 1.52)	0.18 (0.02, 1.35)	1.04 (0.28, 3.89)	standard_dose_rifampicin

Tuberculoma_sscrk_sorted


	x
aspirin	0.172914166666667
levofloxacin	0.260748333333333
standard	0.3295025
standard_dose_rifampicin	0.347305
dexamethasone	0.684600833333333
prednisone	0.834236666666667
methylprednisolone	0.8706925

Supplementary Material 7 Results of research and reanalysis after 2000 AD

Death_2000_anohe



Death_2000_01



Death_2000lth


OR 95%CrI	
aspirin	
1.76 (0.32, 15.21)	ciprofloxacin
0.96 (0.22, 4.45)	0.54 (0.04, 5.05) Clopidogrel
0.93 (0.58, 1.49)	0.53 (0.06, 2.79) 0.97 (0.22, 4.03) dexamethasone
0.4 (0.07, 1.91)	0.22 (0.02, 2.14) 0.41 (0.05, 3.24) 0.42 (0.08, 1.95) Fludrocortisone
1.64 (0.29, 14.3)	0.93 (0.09, 10.02) 1.73 (0.18, 21.51) 1.76 (0.33, 15.07) 4.26 (0.43, 58.75) gatifloxacin

0.68 (0.28, 1.65)	0.39 (0.04, 2.45)	0.71 (0.13, 3.54)	0.74 (0.33, 1.63)	1.73 (0.32, 10.4)	0.41 (0.04, 2.65)	high_dose_rifampicin					
0.75 (0.45, 1.26)	0.43 (0.05, 2.23)	0.78 (0.17, 3.3)	0.81 (0.57, 1.14)	1.9 (0.41, 9.74)	0.46 (0.05, 2.4)	1.1 (0.48, 2.53)	levofloxacin				
1.43 (0.39, 5.4)	0.8 (0.07, 6.55)	1.49 (0.22, 9.79)	1.54 (0.44, 5.53)	3.65 (0.51, 27.93)	0.86 (0.08, 7.07)	2.1 (0.49, 9.1)	1.91 (0.54, 6.95)	linezolid			
1.08 (0.39, 3.15)	0.61 (0.06, 4.22)	1.13 (0.2, 6.24)	1.16 (0.46, 3.1)	2.75 (0.46, 17.87)	0.66 (0.06, 4.53)	1.58 (0.47, 5.53)	1.44 (0.54, 4.01)	0.76 (0.16, 3.64)	methylprednisolone		
0.72 (0.47, 1.1)	0.41 (0.05, 2.13)	0.75 (0.17, 3.07)	0.77 (0.63, 0.94)	1.82 (0.4, 9.15)	0.44 (0.05, 2.31)	1.05 (0.48, 2.29)	0.96 (0.72, 1.28)	0.5 (0.14, 1.72)	0.67 (0.25, 1.68)	standard	
0.26 (0.1, 0.7)	0.15 (0.02, 0.97)	0.27 (0.05, 1.46)	0.28 (0.11, 0.7)	0.67 (0.11, 4.19)	0.16 (0.02, 1.06)	0.39 (0.12, 1.26)	0.35 (0.15, 0.8)	0.18 (0.04, 0.84)	0.24 (0.06, 0.88)	0.37 (0.15, 0.88)	standard_dose_rifampicin


Death_2000scrk_sorted

	X
standard_dose_rifampicin	0.0507472727272727
Fludrocortisone	0.206373636363636
standard	0.343167272727273
high_dose_rifampicin	0.366859545454546
levofloxacin	0.395054090909091
Clopidogrel	
dexamethasone	0.591792727272727
aspirin	0.627719090909091
methylprednisolone	0.630843181818182
linezolid	
gatifloxacin	0.739162727272727
ciprofloxacin	0.762795454545455



Gastrointestinal_2000_anohe



Gastrointestinal_2000_ns



Gastrointestinal_2000_01




Gastrointestinal_2000ltb

OR 95%CrI						
aspirin						
0.32 (0.03, 3.35)	dexamethasone					
0.38 (0.03, 4.91)	1.2 (0.34, 4.17)	high_dose_rifampicin				
0.46 (0.04, 5.01)	1.42 (0.62, 3.32)	1.19 (0.32, 4.5)	levofloxacin			
0.24 (0, 6.98)	0.79 (0.02, 9.17)	0.65 (0.02, 9.44)	0.55 (0.02, 6.65)	linezolid		
0.64 (0.05, 8.64)	1.98 (0.58, 7.48)	1.66 (0.32, 9.16)	1.39 (0.36, 5.84)	2.57 (0.17, 95.98)	methylprednisolone	
0.51 (0.05, 5.08)	1.59 (0.95, 2.72)	1.33 (0.43, 4.23)	1.12 (0.58, 2.18)	2.01 (0.19, 63.5)	0.81 (0.22, 2.62)	standard


Gastrointestinal_2000scrk sorted

	X	
dexamethasone	0.250054166666667	
linezolid	0.317876666666667	
high_dose_rifampicin		0.4047975
levofloxacin		0.4999725
standard	0.603403333333333	
methylprednisolone	0.667946666666667	
aspirin	0.755949166666667	


Hepatic_2000_anohe




Hepatic_2000_ns



Hepatic_2000_01



Compared with standard



Hepatic_2000ltb

OR 95%CrI



aspirin							
0.49 (0.02, 17.87)	dexamethasone						
0.35 (0.01, 15.47)	0.72 (0.17, 2.96)	high_dose_rifampicin					
0.31 (0.01, 11.53)	0.63 (0.31, 1.3)	0.88 (0.21, 3.85)	levofloxacin				
0.88 (0.02, 44.44)	1.79 (0.33, 10.34)	2.49 (0.3, 21.93)	2.82 (0.51, 16.63)	linezolid			
0.62 (0.02, 24)	1.27 (0.53, 3.1)	1.77 (0.37, 8.77)	2 (0.75, 5.46)	0.71 (0.11, 4.42)	methylprednisolone		
0.56 (0.02, 19.96)	1.14 (0.71, 1.83)	1.58 (0.42, 6.25)	1.8 (1.05, 3.13)	0.64 (0.12, 3.25)	0.9 (0.39, 2.05)	standard	

Hepatic_2000scrk sorted



X

levofloxacin							0.165465
high_dose_rifampicin							
dexamethasone							
standard							
methylprednisolone							
aspirin							
linezolid							


Neurological_2000_anohc



Neurological_2000_01



Compared with standard



Neurological_2000lbt


OR 95% CrI

aspirin								
1.28 (0.4, 4.25)	Clopidogrel							
1.04 (0.54, 2.02)	0.81 (0.27, 2.36)	dexamethasone						
1.02 (0.16, 5.92)	0.79 (0.1, 5.63)	0.98 (0.16, 5.28)	high_dose_rifampicin					
0.7 (0.37, 1.35)	0.55 (0.19, 1.59)	0.68 (0.45, 1.02)	0.69 (0.13, 4.19)	levofloxacin				
1.18 (0.26, 5.32)	0.92 (0.16, 5.11)	1.14 (0.27, 4.67)	1.17 (0.13, 10.74)	1.68 (0.41, 6.86)	linezolid			
0.87 (0.49, 1.57)	0.68 (0.24, 1.88)	0.84 (0.62, 1.14)	0.85 (0.16, 5.06)	1.23 (0.94, 1.63)	0.74 (0.19, 2.95)	standard		
3.55 (0.96, 15.78)	2.79 (0.58, 15.08)	3.39 (1.03, 13.78)	3.54 (0.46, 32.25)	5 (1.64, 19.17)	3.03 (0.5, 20.97)	4.06 (1.28, 15.99)	standard_dose_rifampicin	


Neurological_2000scrk_sorted

	X	
levofloxacin	0.135524285714286	
standard	0.338416428571429	
high_dose_rifampicin	0.457538571428571	
aspirin	0.466078571428571	
dexamethasone	0.528337857142857	
linezolid		0.533675
Clopidogrel	0.596366428571429	
standard_dose_rifampicin	0.944062857142857	

Tuberculoma_2000_anohe



Tuberculoma_2000_01



Tuberculoma_2000ltb

OR 95% CrI					
aspirin					
3.99 (0.67, 35.52)	dexamethasone				
1.15 (0.33, 3.95)	0.29 (0.03, 2.19)	levofloxacin			
10.27 (1.19, 314.78)	2.58 (0.19, 84.81)	9.06 (0.83, 311.47)	methylprednisolone		
1.27 (0.73, 2.25)	0.32 (0.04, 1.73)	1.11 (0.37, 3.33)	0.13 (0, 1)	standard	
1.32 (0.31, 5.48)	0.33 (0.03, 2.86)	1.15 (0.55, 2.37)	0.12 (0, 1.55)	1.04 (0.28, 3.81)	standard dose rifampicin

Tuberculoma_2000scrk_sorted

	X
aspirin	0.208069
levofloxacin	0.305327
standard	0.39496
standard_dose_rifampicin	0.405146
dexamethasone	0.760895
methylprednisolone	0.925603